Abstract | BACKGROUND: AIMS AND METHODS: Using the trial's Public Use Dataset, we analyzed factors contributing to symptomatic and asymptomatic intracranial hemorrhage in the 'safety sample' of 830 subjects. RESULTS: CONCLUSIONS: Endovascular thrombolysis was the major factor predisposing to symptomatic intracranial hemorrhage, and albumin contributed to this predisposition. The latter may be mediated by albumin's influence on platelet aggregation or collateral perfusion.
|
Authors | Myron D Ginsberg, Michael D Hill |
Journal | International journal of stroke : official journal of the International Stroke Society
(Int J Stroke)
Vol. 10
Issue 4
Pg. 494-500
(Jun 2015)
ISSN: 1747-4949 [Electronic] United States |
PMID | 25808637
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Copyright | © 2015 World Stroke Organization. |
Chemical References |
- Albumins
- Fibrinolytic Agents
- Tissue Plasminogen Activator
|
Topics |
- Administration, Intravenous
- Aged
- Aged, 80 and over
- Albumins
(therapeutic use)
- Cohort Studies
- Datasets as Topic
- Endovascular Procedures
- Female
- Fibrinolytic Agents
(therapeutic use)
- Humans
- Intracranial Hemorrhages
(etiology, mortality, therapy)
- Male
- Middle Aged
- Severity of Illness Index
- Stroke
(complications, mortality, therapy)
- Thrombolytic Therapy
- Tissue Plasminogen Activator
(therapeutic use)
- Treatment Outcome
|